BioCentury | Jan 25, 2020
Emerging Company Profile

Aluda: targeting the fundamentals

Five years after its launch, Aluda is pulling back the curtain on its pipeline, leading with a first-in-class anti-VIM therapy for fibrotic indications. CEO Ruihuan Chen co-founded Aluda Pharmaceuticals Inc. in 2015 after 13 years...
BC Extra | Nov 15, 2019
Company News

Roche adds to fibrosis portfolio with $390M Promedior acquisition

Roche is adding a Phase III-ready idiopathic pulmonary fibrosis candidate to complement its IPF blockbuster Esbriet pirfenidone via the acquisition of Promedior for $390 million in upfront cash and up to $1 billion in milestones....
BC Week In Review | Apr 26, 2019
Financial News

Continent files for IPO in Hong Kong

Beijing Continent Pharmaceuticals Inc. filed to list on the Hong Kong stock exchange on April 19. The fibrosis company markets Etuary pirfenidone to treat idiopathic pulmonary fibrosis in China; its pipeline includes two liver fibrosis...
BC Extra | Feb 22, 2019
Politics & Policy

China releases list of rare disease drugs with reduced VAT

China’s ministry of finance revealed a list of 21 rare disease drugs and four APIs which will be eligible for a reduction in value-added tax beginning March 1. The government will reduce the VAT on...
BC Innovations | Feb 14, 2019
Emerging Company Profile

Indalo: Integral to fibrosis

Indalo Therapeutics Inc. is targeting the root causes in fibrosis by antagonizing multiple integrins simultaneously to disrupt disease-associated processes, not just those driven by a single integrin or TGFβ signaling. Indalo President and CEO Robert...
BC Week In Review | Jan 4, 2019
Company News

ZappRx, Genentech partner to speed patient access to specialty drugs

Genentech Inc. partnered with ZappRx Inc. (Boston, Mass.) to use the latter's digital platform to improve patient access to specialty drugs for idiopathic pulmonary fibrosis (IPF), with an option to expand into allergic asthma and...
BC Extra | Dec 21, 2018
Company News

ZappRx, Genentech partner to speed patient access to specialty drugs

ZappRx Inc. (Boston, Mass.) will use its digital platform in partnership with Genentech Inc. to improve patient access to specialty drugs for idiopathic pulmonary fibrosis (IPF) with a possible expansion to include allergic asthma and...
BC Week In Review | Sep 21, 2018
Company News

American Thoracic Society releases updated guidelines for IPF diagnosis

The American Thoracic Society and other international respiratory societies released updated guidelines on Aug. 31 for the diagnosis of idiopathic pulmonary fibrosis (IPF), an indication for which there are only two approved therapies. The guidelines...
BioCentury | Jul 13, 2018
Strategy

Roche’s partnering priority

As James Sabry gets set to lead partnering for all of Roche pharma, his first order of business might be to build out the company’s late-stage pipeline ahead of an impending patent cliff that puts...
BC Week In Review | Feb 16, 2018
Clinical News

Kadmon reports Phase II data for IPF candidate

Kadmon Holdings Inc. (NYSE:KDMN) reported top-line data from the U.S. Phase II KD025-207 trial of KD025 to treat idiopathic pulmonary fibrosis (IPF) in patients previously treated with or offered Esbriet pirfenidone or Ofev nintedanib. The...
Items per page:
1 - 10 of 285